These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 32251624)
1. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Barlesi F; Tomasini P Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624 [No Abstract] [Full Text] [Related]
2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248 [TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. Berghoff AS; Venur VA; Preusser M; Ahluwalia MS Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713 [TBL] [Abstract][Full Text] [Related]
4. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint blockade for brain metastases. Harary M; Reardon DA; Iorgulescu JB CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898 [No Abstract] [Full Text] [Related]
6. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002 [TBL] [Abstract][Full Text] [Related]
7. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. Li W; Yu H J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004 [TBL] [Abstract][Full Text] [Related]
8. There and back again: An immunotherapy tale. Guo Y; Krupnick AS J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610 [No Abstract] [Full Text] [Related]
9. KEYNOTE-024: Unlocking a pathway to lung cancer cure? Rusch VW; Chaft J; Hellmann M J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215 [No Abstract] [Full Text] [Related]
10. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis]. Sheng J; Yu X; Li H; Fan Y Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010 [TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
12. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230 [TBL] [Abstract][Full Text] [Related]
13. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review. Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315 [TBL] [Abstract][Full Text] [Related]
14. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis. El Rassy E; Farhat F; Kattan J Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477 [No Abstract] [Full Text] [Related]
15. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670 [TBL] [Abstract][Full Text] [Related]
16. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels. Sibille A; Henket M; Corhay JL; Louis R; Duysinx B Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328 [No Abstract] [Full Text] [Related]
17. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343 [TBL] [Abstract][Full Text] [Related]
18. Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer. Wiesweg M; Mairinger F; Reis H; Goetz M; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; McCutcheon A; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M Ann Oncol; 2019 Apr; 30(4):655-657. PubMed ID: 30753264 [No Abstract] [Full Text] [Related]
19. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Lim SW; Ahn MJ Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418 [TBL] [Abstract][Full Text] [Related]
20. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer]. Jiang WR; Fang LP; Chang N; Zhang J Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]